By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Mesna (monograph)
Drugs

Mesna (monograph)

https://themeditary.com/drug/mesna-monograph-8289.html
Medically Reviewed by Glamora Samuels, MD TheMediTary.Com | Reviewed: Aug 22, 2023  Additional Content by TheMediTary.Com

Generic name: mesnex

Availability: Prescription only

Pregnancy & Lactation: Risk data available

Brand names: Mesnex (oral/injection), Mesna (oral/injection)

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

What is Mesna (monograph)?

Introduction

Uroprotective agent; a synthetic sulfhydryl (thiol) compound.

Uses for Mesna

Prophylaxis of Ifosfamide-induced Hemorrhagic Cystitis

Reduction in the incidence of ifosfamide-induced hemorrhagic cystitis; use recommended by ASCO. Designated an orphan drug by FDA for this use.

Prophylaxis of Cyclophosphamide-induced Hemorrhagic Cystitis

Reduction in the incidence of hemorrhagic cystitis associated with high-dose cyclophosphamide† [off-label] in bone marrow transplantation (BMT) patients; ASCO currently recommends using either mesna plus saline diuresis or forced saline diuresis for this purpose.

Designated an orphan drug by FDA for inhibition of urotoxic effects of oxazaphosphorine compounds (e.g., cyclophosphamide).

Related/similar drugs

Mesnex

Mesna Dosage and Administration

General

  • To maintain adequate urinary protection, administer mesna regimen with each dose of ifosfamide or cyclophosphamide† [off-label].

  • Employ adequate oral and/or IV hydration. To prevent ifosfamide-induced hemorrhagic cystitis, hydrate with at least 1 L of oral or IV fluid daily before and during ifosfamide therapy.

Administration

Administer orally or IV.

Oral Administration

Administer orally.

Prior to availability of oral dosage form, extemporaneous oral solutions were prepared by diluting the appropriate dose of mesna injection† [off-label] in syrup, carbonated beverages, or fruit (i.e., apple, orange) juice. (See Extemporaneous Oral Solutions under Stability.)

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer diluted (20 mg/mL) solution by IV injection.

Has been administered as a 20-mg/mL solution by IV infusion† [off-label] over 15–30 minutes.

Also has been administered by continuous IV infusion† [off-label]. For continuous IV infusion†, may admix with ifosfamide and administer both drugs simultaneously.

Dilution

Withdraw appropriate dose from vial containing 100 mg/mL and dilute with an appropriate volume of a compatible IV solution (see Solution Compatibility under Stability) to obtain a final solution containing 20 mg/mL.

Dosage

Adults

Prophylaxis of Ifosfamide-induced Hemorrhagic Cystitis

If ifosfamide dosage is increased or decreased, maintain constant mesna-to-ifosfamide ratio.

IV

IV injection: For daily ifosfamide dosages <2.5 g/m2, administer a mesna dosage equivalent to 20% weight/weight (w/w) of the daily ifosfamide dosage 15 minutes before or at the time of ifosfamide administration and then at 4 and 8 hours after the ifosfamide dose; total daily mesna dosage is equivalent to 60% w/w of the daily ifosfamide dosage. In patients receiving ifosfamide 1.2 g/m2, administer mesna 240 mg/m2 15 minutes before or at the time of ifosfamide administration, followed by 240 mg/m2 at 4 and 8 hours after the ifosfamide dose.

Continuous IV infusion: For daily ifosfamide dosages <2.5 g/m2, ASCO recommends administering a mesna loading dose equivalent to 20% w/w of the daily ifosfamide dosage by IV injection, followed by 40% w/w of the daily ifosfamide dosage by continuous IV infusion, continued for 12–24 hours after completion of the ifosfamide infusion.

For daily ifosfamide dosages >2.5 g/m2, there are insufficient data to recommend a mesna dosage; however, ASCO recommends more frequent and prolonged administration of mesna for maximum protection against urotoxicity. (See Prescribing Limits.)

IV, then Oral

For daily ifosfamide dosages <2 g/m2, administer a mesna dosage equivalent to 20% w/w of the daily ifosfamide dosage by IV injection at the time of ifosfamide administration, followed by 40% w/w of the daily ifosfamide dosage orally at 2 and 6 hours after the ifosfamide dose; total daily mesna dosage is equivalent to 100% w/w of the daily ifosfamide dosage.

In patients receiving 1.2 g/m2 of ifosfamide, administer mesna 240 mg/m2 by IV injection at the time of ifosfamide administration, followed by 480 mg/m2 orally at 2 and 6 hours after the ifosfamide dose.

If patient vomits oral dose within 2 hours of administration, repeat dose or consider IV administration.

Prophylaxis of Cyclophosphamide-induced† Hemorrhagic Cystitis
IV

Mesna dosage equivalent to 60–160% w/w of the daily cyclophosphamide dosage, given by IV injection (in 3–5 divided doses daily) or by continuous IV infusion (continued for ≥24 hours after cyclophosphamide is discontinued).

Prescribing Limits

Adults

Prophylaxis of Ifosfamide-induced Hemorrhagic Cystitis
IV

Maximum mesna dosage equivalent to 60% w/w of the daily ifosfamide dosage.

Safety and efficacy of the recommended mesna-to-ifosfamide ratio (see Dosage) not established for ifosfamide dosages >2.5 g/m2 daily.

IV, then Oral

Safety and efficacy of the recommended mesna-to-ifosfamide ratio (see Dosage) not established for ifosfamide dosages >2 g/m2 daily.

Special Populations

Geriatric Patients

Cautious dosing recommended; always maintain constant mesna-to-ifosfamide ratio. (See Geriatric Use under Cautions.)

Detailed Mesna dosage information

Warnings

Contraindications

  • Known hypersensitivity to mesna or other sulfhydryl (thiol) compounds.

Warnings/Precautions

Warnings

Therapy Limitations

Does not prevent ifosfamide- or cyclophosphamide-induced hemorrhagic cystitis in all patients. Prior to each scheduled ifosfamide dose, examine morning urine specimen for presence of erythrocytes. If hematuria (>50 erythrocytes/HPF or WHO ≥grade 2) occurs despite mesna prophylaxis, reduce ifosfamide or cyclophosphamide dosage or discontinue these antineoplastic agents.

Does not prevent ifosfamide-induced nephrotoxicity or other nonurologic toxicities (e.g., myelosuppression, neurotoxicity, alopecia). Does not reduce risk of hematuria associated with other conditions such as thrombocytopenia.

Sensitivity Reactions

Hypersensitivity and Anaphylactic Reactions

Hypersensitivity reactions (e.g., pruritus, rash, generalized urticaria, decreased platelet counts, facial edema ) and anaphylaxis reported. Increased incidence of hypersensitivity reactions in patients with autoimmune disorders receiving cyclophosphamide and mesna; most patients received mesna orally.

Hypersensitivity reactions may respond to antihistamines and corticosteroids.

General Precautions

Lactose Intolerance

Each 400-mg Mesnex tablet contains 59.3 mg lactose; patients with a history of lactose intolerance may be sensitive to this formulation of the drug.

Specific Populations

Pregnancy

Category B.

Lactation

Not known whether mesna or dimesna is distributed into human milk. Discontinue nursing or the drug.

Pediatric Use

Safety and efficacy not established; however, has been used in infants as young as 4 months of age without unusual adverse effects.

Large amounts of benzyl alcohol (i.e., 100–400 mg/kg daily) have been associated with toxicity in neonates; each mL of mesna in multidose vials contains 1.04 mg of benzyl alcohol. Do not use multidose vials in neonates and infants (see Preparations for information regarding preservative-free preparation); use multidose vials with caution in children and adolescents.

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults. Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and potential for concomitant disease and drug therapy. (See Geriatric Patients under Dosage and Administration.)

Common Adverse Effects

Mesna monotherapy: Headache, injection site reactions, flushing, dizziness, nausea, vomiting, somnolence, diarrhea, anorexia, fever, pharyngitis, hyperesthesia, influenza-like symptoms, coughing, constipation, flatulence, rhinitis, rigors, back pain, rash, conjunctivitis, arthralgia.

Mesna with ifosfamide: Nausea, vomiting, constipation, leukopenia, fatigue, fever, anorexia, thrombocytopenia, anemia, granulocytopenia, asthenia, abdominal pain, alopecia, dyspnea, chest pain, hypokalemia, diarrhea, dizziness, headache, pain, increased sweating, back pain, hematuria, injection site reaction, edema, peripheral edema, somnolence, anxiety, confusion, facial edema, insomnia, coughing, dyspepsia, hypotension, pallor, dehydration, pneumonia, tachycardia, flushing.

How should I use Mesna (monograph)

General

  • To maintain adequate urinary protection, administer mesna regimen with each dose of ifosfamide or cyclophosphamide† [off-label].

  • Employ adequate oral and/or IV hydration. To prevent ifosfamide-induced hemorrhagic cystitis, hydrate with at least 1 L of oral or IV fluid daily before and during ifosfamide therapy.

Administration

Administer orally or IV.

Oral Administration

Administer orally.

Prior to availability of oral dosage form, extemporaneous oral solutions were prepared by diluting the appropriate dose of mesna injection† [off-label] in syrup, carbonated beverages, or fruit (i.e., apple, orange) juice. (See Extemporaneous Oral Solutions under Stability.)

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer diluted (20 mg/mL) solution by IV injection.

Has been administered as a 20-mg/mL solution by IV infusion† [off-label] over 15–30 minutes.

Also has been administered by continuous IV infusion† [off-label]. For continuous IV infusion†, may admix with ifosfamide and administer both drugs simultaneously.

Dilution

Withdraw appropriate dose from vial containing 100 mg/mL and dilute with an appropriate volume of a compatible IV solution (see Solution Compatibility under Stability) to obtain a final solution containing 20 mg/mL.

Dosage

Adults

Prophylaxis of Ifosfamide-induced Hemorrhagic Cystitis

If ifosfamide dosage is increased or decreased, maintain constant mesna-to-ifosfamide ratio.

IV

IV injection: For daily ifosfamide dosages <2.5 g/m2, administer a mesna dosage equivalent to 20% weight/weight (w/w) of the daily ifosfamide dosage 15 minutes before or at the time of ifosfamide administration and then at 4 and 8 hours after the ifosfamide dose; total daily mesna dosage is equivalent to 60% w/w of the daily ifosfamide dosage. In patients receiving ifosfamide 1.2 g/m2, administer mesna 240 mg/m2 15 minutes before or at the time of ifosfamide administration, followed by 240 mg/m2 at 4 and 8 hours after the ifosfamide dose.

Continuous IV infusion: For daily ifosfamide dosages <2.5 g/m2, ASCO recommends administering a mesna loading dose equivalent to 20% w/w of the daily ifosfamide dosage by IV injection, followed by 40% w/w of the daily ifosfamide dosage by continuous IV infusion, continued for 12–24 hours after completion of the ifosfamide infusion.

For daily ifosfamide dosages >2.5 g/m2, there are insufficient data to recommend a mesna dosage; however, ASCO recommends more frequent and prolonged administration of mesna for maximum protection against urotoxicity. (See Prescribing Limits.)

IV, then Oral

For daily ifosfamide dosages <2 g/m2, administer a mesna dosage equivalent to 20% w/w of the daily ifosfamide dosage by IV injection at the time of ifosfamide administration, followed by 40% w/w of the daily ifosfamide dosage orally at 2 and 6 hours after the ifosfamide dose; total daily mesna dosage is equivalent to 100% w/w of the daily ifosfamide dosage.

In patients receiving 1.2 g/m2 of ifosfamide, administer mesna 240 mg/m2 by IV injection at the time of ifosfamide administration, followed by 480 mg/m2 orally at 2 and 6 hours after the ifosfamide dose.

If patient vomits oral dose within 2 hours of administration, repeat dose or consider IV administration.

Prophylaxis of Cyclophosphamide-induced† Hemorrhagic Cystitis
IV

Mesna dosage equivalent to 60–160% w/w of the daily cyclophosphamide dosage, given by IV injection (in 3–5 divided doses daily) or by continuous IV infusion (continued for ≥24 hours after cyclophosphamide is discontinued).

Prescribing Limits

Adults

Prophylaxis of Ifosfamide-induced Hemorrhagic Cystitis
IV

Maximum mesna dosage equivalent to 60% w/w of the daily ifosfamide dosage.

Safety and efficacy of the recommended mesna-to-ifosfamide ratio (see Dosage) not established for ifosfamide dosages >2.5 g/m2 daily.

IV, then Oral

Safety and efficacy of the recommended mesna-to-ifosfamide ratio (see Dosage) not established for ifosfamide dosages >2 g/m2 daily.

Special Populations

Geriatric Patients

Cautious dosing recommended; always maintain constant mesna-to-ifosfamide ratio. (See Geriatric Use under Cautions.)

Detailed Mesna dosage information
Mesna (monograph) Dosage information (more detail)

What other drugs will affect Mesna (monograph)?

No formal drug interaction studies to date.

Specific Drugs, Therapies, and Laboratory Tests

Drug, Therapy, or Test

Interaction

Comments

Antineoplastic agents (cyclophosphamide, doxorubicin, ifosfamide, methotrexate, vincristine)

Pharmacologic interaction (loss of antineoplastic effects) unlikely

Irradiation, total body

Pharmacologic interaction (loss of antineoplastic effects) unlikely

May safely use with regimens that include total body irradiation

Sodium nitroprusside tests for urinary ketones

Possible false-positive results due to interaction between sulfonate group in mesna and sodium nitroprusside reagent

More about Mesna (monograph) (Mesnex)

Dosage information
Mesna (monograph) Side Effects
During pregnancy
Mesna Prescribing Information
Drug images
Side effects
Breastfeeding Warnings
Drug class: Drugs

Related treatment guides

Hemorrhagic Cystitis Prophylaxis
Share this Article
Contents
Uses Warnings Before Taking Dosage Side effects Interactions
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by